In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a price target of $15.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Emergent Biosolutions’ operational efficiency and strategic advancements. Despite a slight miss in top-line revenue for the first quarter of 2025, the company exceeded expectations in net income, demonstrating strong operational efficiency. Emergent’s reaffirmation of its revenue guidance for the year and its ability to surpass earnings estimates by a significant margin underscore its financial stability and potential for continued growth.
Furthermore, several recent developments bolster the company’s portfolio strength, including new contracts and collaborations. Notable achievements include a $20 million contract with the U.S. Department of Defense, a $16.7 million development collaboration with BARDA, and a $65 million agreement with the Ontario Ministry of Health. These strategic moves, along with the sale of non-core assets and a focus on optimizing long-term growth, position Emergent Biosolutions well for future success, justifying the Buy rating.
In another report released on May 8, Benchmark Co. also maintained a Buy rating on the stock with a $12.00 price target.